一个 in silico 框架,用于合理设计阴道益生菌疗法
Christina Y Lee1, Sina Bonakdar1, Kelly B Arnold1
1Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
PLoS computational biology
|February 14, 2025
概括
开发新的细菌性阴道炎 (BV) 治疗方法是一项挑战. 一个in silico框架有助于益生菌选择和优化剂量策略,改善复发性BV管理.
科学领域:
- 微生物学 微生物学
- 计算生物学 计算生物学
- 妇女健康 妇女健康
背景情况:
- 细菌性阴道炎 (BV) 是一种常见的阴道微生物组不平衡,与不良的生殖健康结果和增加性传播疾病易感性有关.
- 目前针对BV的抗生素治疗在预防复发方面有效性有限,阻碍了新生物疗法的开发.
- 缺乏可控模型阻碍了对新治疗方案的评估,包括益生菌干预.
研究的目的:
- 开发和验证一个in silico计算框架,用于评估益生菌菌株选择标准.
- 评估用于BV治疗的辅助抗生素治疗和替代剂量策略的潜力.
- 确定关键的微生物相互作用参数,这些参数对于在BV的背景下益生菌的有效性至关重要.
主要方法:
- 开发一个模拟阴道微生物组动态的计算框架.
- 假设的益生菌菌株和它们与居住细菌的相互作用的in silico测试.
- 对辅助抗生素治疗和各种益生菌剂量频率的评估.
- 计算模型与2b期临床试验数据的验证.
主要成果:
- 计算框架确定了居住细菌和益生菌菌株之间的特定相互作用参数,这些参数对疗效至关重要.
- 模型预测成功地复制了2b期临床试验对活体生物治疗药物Lactin-V的结果.
- 结果表明,Lactin-V益生菌需要辅助抗生素治疗才能有效.
- 增加益生菌剂量频率可能会对12周和24周的BV复发率产生适度影响.
结论:
- 开发的in silico框架为合理选择用于BV治疗的益生菌菌株提供了有价值的工具.
- 该模型有助于优化生物治疗干预的剂量策略和辅助疗法.
- 这种计算方法可以加快对复发性细菌性阴道炎的更有效治疗方法的开发.
相关概念视频
01:10In Vitro Drug Release Testing: Overview, Development and Validation
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:22Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
01:30Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
01:28Microbiota of the Urogenital Tract
The human urogenital system, once thought to be sterile in healthy individuals, is now recognized as a complex microbial habitat. Advancements in molecular sequencing techniques have revealed that even in healthy adults, the kidneys and bladder harbor microbial populations similar to those found in the distal urethra, albeit in much lower abundance. These resident microorganisms, while generally innocuous, can become opportunistic pathogens under conditions that alter the urogenital...